XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2024
shares
Trading Arrangements, by Individual  
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Myriam J. Curet, M.D [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
On August 13, 2024, Myriam J. Curet, M.D., FACS, the Company’s Executive Vice President and Chief Medical Officer, adopted a Rule 10b5-1 trading plan. Dr. Curet’s trading plan provides for the potential sale of up to 33,581 shares of the Company’s common stock, including the potential exercise and sale of up to 21,966 shares of the Company’s common stock subject to stock options, until August 13, 2025. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and the Company’s policies regarding transactions in the Company’s securities.
Name Myriam J. Curet, M.D.
Title FACS, the Company’s Executive Vice President and Chief Medical Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date August 13, 2024
Expiration Date August 13, 2025
Arrangement Duration 365 days
Aggregate Available 33,581
Myriam J. Curet, M.D. Trading Arrangement, Vested Options [Member] | Myriam J. Curet, M.D [Member]  
Trading Arrangements, by Individual  
Aggregate Available 21,966